Bronchiolitis Obliterans Syndrome (BOS) Recruiting Phase 2 Trials for Nintedanib (DB09079)

Also known as: Obliterative Bronchiolitis / Bronchiolitis Obliterans / Bronchiolitis Obliterans (BO) / Bronchiolitis Obliterans Syndrome / Obliterative bronchiolitis (disorder)

IndicationStatusPhase
DBCOND0071683 (Bronchiolitis Obliterans Syndrome (BOS))Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03805477Nintedanib in Patients With Bronchiolitis Obliterans Syndrome Following Hematopoietic Stem Cell TransplantationTreatment